Business Wire

ADVA

27.1.2022 09:02:14 CET | Business Wire | Press release

Share
Terralpha harnesses ADVA TeraFlex™ for 600G transport throughout France

ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/

“With around 20,000km of fiber deployed alongside our railway infrastructure, we knew we were in a unique position to offer super-fast connectivity right across France. What we needed was a transport solution with the capacity, flexibility and scale to match our ambitions and a partner we could trust. In ADVA, we have a European technology provider with a wealth of experience and an excellent track record for success,” said Gabriel Chenevoy, CEO of Terralpha. “The ADVA team has worked with us to deliver a solution that maximizes the value of our existing network and empowers us to provide our customers with a new level of bandwidth capacity and service quality. Our backbone infrastructure will be key to closing the digital divide by delivering high-speed services in a highly efficient and sustainable way to around 100 tier 3 cities within two years. The performance of ADVA’s equipment combined with our straight and diverse routes has enabled us to reduce actual latencies between major cities in France from 10% to 40%, supporting new latency-sensitive applications.”

The ADVA FSP 3000 TeraFlex terminal is specifically designed to inject enormous capacity into deployed networks without operators having to spend significant amounts on overhauling their infrastructure. With its software-defined fractional QAM modulation and adaptive baud rate capabilities, the low-power 1RU terminal is now ensuring optimal spectrum utilization in Terralpha’s transport system. The network is managed by ADVA’s Ensemble Controller, which supports programmatic SDN control, further improving efficiency by reducing troublesome and time-consuming manual processes. The infrastructure is also continuously assured by ADVA’s ALM fiber monitoring technology with precise fault localization from Ensemble Fiber Director. This enables Terralpha’s maintenance teams to quickly detect and pinpoint any degradation in the fiber plant and resolve issues before services are affected.

“We’re helping Terralpha to unlock the full value of its fiber assets. By harnessing our technology and the expertise of our engineers, Terralpha can take advantage of its vast network architecture to bring reliable, low-latency services at unprecedented speeds to homes, businesses and service provider customers in every corner of France,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “One of the keys to the success of this project has been our close collaboration with the Terralpha team to make sure the new solution meets their exact requirements. That’s helped us deliver a turnkey solution that works seamlessly with Terralpha’s existing network to provide optimal performance over every single link. With our scalable technology and continuing support, there’s no limit to what Terralpha can achieve.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Terralpha

Incorporated in 2021, Terralpha, a 100% subsidiary of SNCF Réseau, offers Ultra High Speed data transport services. Its DNA “Ultra High Speed for all territories” is supported by an ambition to deploy Ultra High Speed and high reliability points of presence throughout France. The choice of architecture and transmission equipment, of European origin, enables to create circuits between cities at speeds of 100Gb/s to 600Gb/s at very low latency.

Terralpha’s mission is to ensure the trusted routing of data traffic through fully owned active and passive infrastructure. Additionally, and in order to facilitate the development of regional data centers, Terralpha offers a range of hosting solutions called ”Digital Tiles” to host the equipment necessary for the storage and the processing of information locally. Each of these “Digital Tiles” has a dual fiber connection to the Terralpha network, and to the public networks to meet the strategic requirements of data centers. www.terralpha.fr

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye